Prospectively Curing Inequitable Conduct through Reissue: Reconsidering a "Well-Settled Principle"

By Klein, Daniel A. | Santa Clara Computer & High Technology Law Journal, March 2010 | Go to article overview

Prospectively Curing Inequitable Conduct through Reissue: Reconsidering a "Well-Settled Principle"


Klein, Daniel A., Santa Clara Computer & High Technology Law Journal


I. Introduction

Inequitable conduct is an equitable doctrine that renders a patent unenforceable upon a finding that the patentee has breached the duty of candor and good faith owed to the U.S. Patent and Trademark Office ("PTO") during prosecution of a patent application. (1) The duty of candor includes the requirement to submit to the PTO information material to patentability of a pending claim, (2) and a holding of inequitable conduct can be based on the failure to disclose such information to the PTO, if the applicant acted with deceptive intent. (3) Moreover, the duty is owed not only by the applicant, i.e., the named inventor(s), but also by "[e]ach attorney or agent who prepares or prosecutes the application; and [e]very other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application." (4)

In Aventis Pharma S.A. v. Amphastar Pharmaceuticals, the Court of Appeals for the Federal Circuit affirmed the district court's holding that Aventis's asserted patent was unenforceable for inequitable conduct. (5) The conduct in question consisted of the failure to disclose certain information concerning data and associated assertions contained in the patent's specification and in declarations submitted during prosecution. (6) Finding these omissions intentional, and that but for the intentional omissions the patent would likely not have issued, the district court held the patent unenforceable. (7)

Prior to filing its infringement action, Aventis filed an application to reissue its patent. (8) In its reissue application, Aventis expressly disavowed reliance on all arguments proffered during prosecution of the original patent that were based on the data in question. (9) The reissue patent issued one day before the district court's order, and the court extended the judgment of unenforceability of the original patent to the reissue patent. (10) The Federal Circuit affirmed, citing the "well-settled principle ... that a reissue proceeding cannot rehabilitate a patent held to be unenforceable due to inequitable conduct." (11)

This article examines the Aventis court's opinion that the judgment of unenforceability of the original patent automatically extended to the reissue patent, and concludes that the court was in error. Section II of the article reviews the facts and critiques the reasoning behind the holding of inequitable conduct in Aventis. Section III considers under what circumstances a patentee should be able to prospectively cure conduct that otherwise would be held inequitable conduct. Section IV examines how the outcome might have been different in Aventis and other cases had the court followed this article's reasoning. Section V briefly summarizes the conclusions drawn.

II. INEQUITABLE CONDUCT IN A VENTIS V. AMPHASTAR

A. The '618 Patent

Aventis markets the drug LOVENOX(r), useful for preventing thromboses (blood clotting) while minimizing the possibility of hemorrhaging, especially during high-risk surgery. (12) Amphastar and Teva each filed an Abbreviated New Drug Application ("ANDA") in order to obtain approval from the Food and Drug Administration ("FDA") to market a generic version of LOVENOX[R]. (13) Consequently, Aventis sued both parties for infringement of U.S. Patent No. 5,389,618 ("the '618 patent"), listed in the FDA's Orange Book for LOVENOX[R]. (14)

The defendants' ANDAs contained a paragraph IV certification (15) alleging, inter alia, that the '618 patent was unenforceable due to inequitable conduct. (16) The assertion of inequitable conduct (with which the district court agreed) was premised on Example 6 of the '618 patent's specification and statements concerning Example 6 by declarant Dr. Andre Uzan. (17) The '618 patent is directed to a composition comprising low molecular weight heparins ("LMWHs"). …

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

Prospectively Curing Inequitable Conduct through Reissue: Reconsidering a "Well-Settled Principle"
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

"Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited passage

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.